Education
About Us
Working with TipRanks
Follow Us
Edgewise Therapeutics, Inc. (EWTX)
:EWTX
EWTX Analyst Ratings
Strong Buy
9 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
EWTX Stock 12 Month Forecast
Average Price Target
$37.55
▲(157.19% Upside)
| Highest Price Target$51.00 | Average Price Target$37.55 | Lowest Price Target$14.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
J.P. Morgan
$40→$30
Buy
105.48%
Upside
Reiterated
08/19/25
H.C. Wainwright
$42
Buy
187.67%
Upside
Reiterated
08/08/25
Evercore ISI
$40→$30
Buy
105.48%
Upside
Reiterated
08/07/25
Leerink Partners
$50
Buy
242.47%
Upside
Reiterated
08/07/25
Analysts' Top Healthcare Picks: Immunic (IMUX), Edgewise Therapeutics (EWTX)We now wait for the GRAND CANYON topline readout in 4Q26. In DMD, EWTX thinks that a 10 mg dose appears to have a profile that can move forward to a Phase 3 study after several rounds of dose exploration. Recall, EWTX shared data earlier this year that demonstrated that patients who remained on 10 mg for the majority of the study were doing well on functional outcomes, with cohorts 2 and 3 showing a +2.2 difference on NSAA and +0.3 on SV95C vs. predicted natural history (here).
Raymond James
$46
Buy
215.07%
Upside
Reiterated
08/07/25
RBC Capital
$48→$49
Buy
235.62%
Upside
Reiterated
08/07/25
Wedbush
$40→$35
Buy
139.73%
Upside
Reiterated
06/27/25
Scotiabank
$14
Hold
-4.11%
Downside
Reiterated
06/27/25
Truist Financial
$50
Buy
242.47%
Upside
Reiterated
06/26/25
Stifel Nicolaus
$16
Hold
9.59%
Upside
Reiterated
06/26/25
Piper Sandler
$51
Buy
249.32%
Upside
Reiterated
06/11/25
Guggenheim
$41
Buy
180.82%
Upside
Initiated
04/30/25
TR | OpenAI - 4o
―
Sell
―
Downgraded
04/22/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
J.P. Morgan
$40→$30
Buy
105.48%
Upside
Reiterated
08/19/25
H.C. Wainwright
$42
Buy
187.67%
Upside
Reiterated
08/08/25
Evercore ISI
$40→$30
Buy
105.48%
Upside
Reiterated
08/07/25
Leerink Partners
$50
Buy
242.47%
Upside
Reiterated
08/07/25
Analysts' Top Healthcare Picks: Immunic (IMUX), Edgewise Therapeutics (EWTX)We now wait for the GRAND CANYON topline readout in 4Q26. In DMD, EWTX thinks that a 10 mg dose appears to have a profile that can move forward to a Phase 3 study after several rounds of dose exploration. Recall, EWTX shared data earlier this year that demonstrated that patients who remained on 10 mg for the majority of the study were doing well on functional outcomes, with cohorts 2 and 3 showing a +2.2 difference on NSAA and +0.3 on SV95C vs. predicted natural history (here).
Raymond James
$46
Buy
215.07%
Upside
Reiterated
08/07/25
RBC Capital
$48→$49
Buy
235.62%
Upside
Reiterated
08/07/25
Wedbush
$40→$35
Buy
139.73%
Upside
Reiterated
06/27/25
Scotiabank
$14
Hold
-4.11%
Downside
Reiterated
06/27/25
Truist Financial
$50
Buy
242.47%
Upside
Reiterated
06/26/25
Stifel Nicolaus
$16
Hold
9.59%
Upside
Reiterated
06/26/25
Piper Sandler
$51
Buy
249.32%
Upside
Reiterated
06/11/25
Guggenheim
$41
Buy
180.82%
Upside
Initiated
04/30/25
TR | OpenAI - 4o
―
Sell
―
Downgraded
04/22/25
Best Analysts Covering Edgewise Therapeutics
1 Month
xxx
Success Rate
11/16 ratings generated profit
Average Return
+1.64%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 68.75% of your transactions generating a profit, with an average return of +1.64% per trade.
3 Months
xxx
Success Rate
10/16 ratings generated profit
Average Return
+31.49%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +31.49% per trade.
1 Year
Success Rate
14/26 ratings generated profit
Average Return
+53.20%
reiterated a buy rating 22 days ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +53.20% per trade.
2 Years
xxx
Success Rate
17/27 ratings generated profit
Average Return
+59.20%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 62.96% of your transactions generating a profit, with an average return of +59.20% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
EWTX Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
15
18
17
12
14
Buy
4
4
3
2
2
Hold
6
7
6
3
2
Sell
4
4
1
0
0
Strong Sell
0
0
0
0
0
total
29
33
27
17
18
Each month's total comprises the sum of three months' worth of ratings.
EWTX Financial Forecast
EWTX Stock Forecast FAQ
What is EWTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Edgewise Therapeutics, Inc.’s 12-month average price target is 37.55.
What is EWTX’s upside potential, based on the analysts’ average price target?
Edgewise Therapeutics, Inc. has 157.19% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is EWTX a Buy, Sell or Hold?
Edgewise Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 9 buy ratings, 2 hold ratings and 0 sell ratings.
What is Edgewise Therapeutics, Inc.’s price target?
The average price target for Edgewise Therapeutics, Inc. is 37.55. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $51.00 ,the lowest forecast is $14.00. The average price target represents 157.19% Increase from the current price of $14.6.
The highest analyst price target is $51.00 ,the lowest forecast is $14.00. The average price target represents 157.19% Increase from the current price of $14.6.
What do analysts say about Edgewise Therapeutics, Inc.?
Edgewise Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of EWTX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.